Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel (Registered Trademark) + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Next Previous
X
Search
Trial Profile

A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel (Registered Trademark) + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agatolimod (Primary) ; Aluminium hydroxide (Primary) ; Malaria vaccine (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 04 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Planned end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Status changed from recruiting to not yet recruiting, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top